NYSEAMERICAN:ATNM

Actinium Pharmaceuticals Stock Forecast, Price & News

$7.46
-0.11 (-1.45 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$7.37
Now: $7.46
$7.61
50-Day Range
$7.80
MA: $10.35
$11.82
52-Week Range
$4.71
Now: $7.46
$19.47
Volume185,325 shs
Average Volume396,157 shs
Market Capitalization$143.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
Actinium Pharmaceuticals logo

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ATNM
CUSIPN/A
CIKN/A
Phone+1-646-6773875
Employees30
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.03 per share

Profitability

Net Income$-21,900,000.00

Miscellaneous

Market Cap$143.58 million
Next Earnings DateN/A
OptionableOptionable

Headlines

Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
April 6, 2021 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

574th out of 2,024 stocks

Pharmaceutical Preparations Industry

273rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$7.46
-0.11 (-1.45 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

Is Actinium Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Actinium Pharmaceuticals stock.
View analyst ratings for Actinium Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Actinium Pharmaceuticals?

Wall Street analysts have given Actinium Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Actinium Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its quarterly earnings results on Tuesday, March, 30th. The biotechnology company reported ($0.37) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.37).
View Actinium Pharmaceuticals' earnings history
.

How has Actinium Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Actinium Pharmaceuticals' stock was trading at $0.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATNM shares have increased by 3,008.3% and is now trading at $7.46.
View which stocks have been most impacted by COVID-19
.

When did Actinium Pharmaceuticals' stock split? How did Actinium Pharmaceuticals' stock split work?

Actinium Pharmaceuticals shares reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of Actinium Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for ATNM?

4 analysts have issued 1 year target prices for Actinium Pharmaceuticals' stock. Their forecasts range from $25.00 to $57.00. On average, they anticipate Actinium Pharmaceuticals' share price to reach $41.00 in the next twelve months. This suggests a possible upside of 449.6% from the stock's current price.
View analysts' price targets for Actinium Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the following people:
  • Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (Age 57, Pay $861.35k)
  • Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (Age 35, Pay $378.55k)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific & Technology Officer (Age 59, Pay $432.25k)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 66, Pay $490k)
  • Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang, VP & Head of Radiation Sciences
  • Dr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale, VP & Global Head of Regulatory Affairs
  • Dr. Avinash Desai, Exec. VP of Clinical Devel., Operations & Medical Affairs

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $7.46.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals has a market capitalization of $143.58 million.

How many employees does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals employs 30 workers across the globe.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com.

Where are Actinium Pharmaceuticals' headquarters?

Actinium Pharmaceuticals is headquartered at 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.